Company Overview and News

 
BLOK Technologies Announces Appointment of Yari Nieken to the Board of Directors

2018-10-13 globenewswire
VANCOUVER, British Columbia, Oct. 12, 2018 (GLOBE NEWSWIRE) -- BLOK Technologies Inc. ("BLOK Tech" or the "Company") (CSE: BLK) (FRANKFURT: 2AD) (OTC: BLPFF) is pleased to announce the appointment of Yari Nieken as a Director of the company. Mr. Nieken has a wide range of public company and capital market experience, and is Founder and President of Foremost Capital Inc. an Exempt Market Dealer in British Columbia.
VRT LES VRTHF PHLMF PUFXF PUF BLPFF

 
Veritas Pharma Attending CannX International Medical Cannabis Conference in Tel Aviv, Israel

2018-10-11 globenewswire
VANCOUVER, British Columbia, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that its CEO Dr. Lui Franciosi and Medical Director Dr. Scott Alexander will be attending the 3rd International Medical Cannabis Conference, or (“CannX”) in Tel Aviv, Israel from October 14 to 16, 2018.
VRT VRTHF

 
Veritas Signs MOU with Leader in Puerto Rico’s Medicinal Cannabis Market

2018-10-05 globenewswire
VANCOUVER, B.C., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce along with the Institute for Medical Cannabis (the “IMC”) of Puerto Rico, the signing of a Memorandum of Understanding (“MOU”) between the two entities for the investigation and commercialization of new pharmaceutical products within the Commonwealth of Puerto Rico.
VRT VRTHF

 
Veritas’ Cannevert to Offer Testing Services for Cannabis & Hemp Licensed Producers; Corporate Update

2018-09-19 globenewswire
VANCOUVER, British Columbia, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to provide a corporate update on its activities, milestones over the first three quarters of 2018, and strategies for growth in the new year.
VRT LES VRTHF

 
3 Carbon Extractions Enters into Collaboration with CannabisWise Accreditation

2018-09-13 globenewswire
VANCOUVER, British Columbia, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that 3 Carbon Extractions Inc. (“3 CARBON”), an industry leader in regulatory compliant cannabis hydrocarbon extraction solutions, has entered into a collaboration with CannabisWise to provide expert advice on standards for cannabis extracts.
VRT VRTHF

 
Veritas Enters Into LOI for Sale of Sechelt Organic Marijuana

2018-09-13 globenewswire
VANCOUVER, British Columbia, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that the Company has entered into a Non-Binding Letter of Intent (“LOI”) to sell all of the issued and outstanding common shares of Sechelt Organic Marijuana Inc. (“Sechelt”) to Leis Industries Limited (“Leis”).
VRT LES VRTHF

 
Veritas Welcomes MOU Between 3 Carbon Extractions and Rubikon Blockchain

2018-09-11 globenewswire
VANCOUVER, British Columbia, Sept. 11, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that 3 Carbon Extractions Inc. (“3 CARBON”), an industry leader in regulatory compliant cannabis hydrocarbon extraction solutions, has entered into a Memorandum of Understanding (“MOU”) with Rubikon Blockchain Corporation (“Rubikon”) to establish secure infrastructure for the tracking of manufacturing equipment and the processing of cannabis extracts.
VRT VRTHF

 
Veritas Welcomes Exclusive Marketing Agreement Between 3 Carbon Extractions and ExtractionTek Solutions

2018-09-05 globenewswire
VANCOUVER, British Columbia, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that its subsidiary, 3 Carbon Extractions Inc. (“3 CARBON”), has completed an exclusive marketing rights relationship with ExtractionTek Solutions Inc. (“ETS”) located in Denver, Colorado, U.S.
VRT VRTHF

 
Veritas Appoints Lorne Mark Roseborough CEO of SunVault Energy to the Board of Directors

2018-09-04 globenewswire
VANCOUVER, British Columbia, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce the appointment of Lorne Mark Roseborough as a Director of the Company.
VRT VRTHF SVLT

1
Veritas Completes Share Purchase Agreement with 3 Carbon Extractions Inc.

2018-08-27 globenewswire - 1
VANCOUVER, British Columbia, Aug. 27, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that the Company has completed the Share Purchase Agreement (“Purchase Agreement”) to acquire Fifty Percent (50%) of the issued and outstanding shares of 3 Carbon Extractions Inc. (“3 CARBON”).
VRT VRTHF

 
Veritas Signs MOU with Israeli Cannabis Industry Leader IsCann Group Limited

2018-08-15 globenewswire
VANCOUVER, British Columbia, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that it has signed a Memorandum of Understanding (“MOU”) with IsCann Group Limited (“IsCann”) located in Be'er Tuvya, Israel with the aim of establishing, maintaining, and expanding business in the Canadian and Israeli medical cannabis sector.
VRT VRTHF

92
Frankfurt’s Clearstream Banking Lifts Settlement Restrictions on Securities Active in Medical Cannabis

2018-08-08 globenewswire
VANCOUVER, British Columbia, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that Clearstream Banking, a major central securities depository based in Frankfurt, Germany, which announced on June 25, 2018 that it would stop dealing with all North American cannabis stocks, has revised its decision to now solely deal with companies focused on medical cannabis such as Veritas.
TWMJF ACB VRT WEED ACBFF VRTHF CGC GWP

1
Veritas Pharma Announces Loan to Marapharm and Cancellation of Stock Options

2018-07-27 globenewswire - 1
VANCOUVER, British Columbia, July 27, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that effective June 25, 2018, it cancelled a total of 3,272,000 incentive stock options (“Options”) granted under the Company’s stock option plan (the “Option Plan”) to consultants, directors of the Company. The cancelled Options were voluntarily surrendered by the holder thereof for no consideration.
VRT MDM VRTHF MRPHF

 
Veritas Pharma Signs IP Agreement with UK’s First Medicinal Cannabis Investment Fund

2018-07-17 globenewswire
VANCOUVER, British Columbia, July 17, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP), (“Veritas” or the “Company”) is pleased to announce that it has signed an Intellectual Property Sharing Agreement (“Joint IP”) with Sativa Investments PLC (“Sativa”) (NEX:SATI), UK’s first medicinal cannabis investment fund.
VRT VRTHF

 
SHARC Wins Canadian Prestigious Water Canada’s Industry Award

2018-07-09 globenewswire
VANCOUVER, British Columbia, July 09, 2018 (GLOBE NEWSWIRE) -- Sharc International Systems Inc. (CSE:SHRC) (FSE:IWIA) (OTCQB:INTWF) ("SHARC" or "the Company") is pleased to announce that the Company’s revolutionary SHARC™ wastewater heat exchange system has won three top awards at the prestigious Water’s Next Award program that honours the achievements of individuals and companies that successfully improve freshwater in Canada.
LEDIF VRT MDM VRTHF AQSZF LMD MRPHF AQS

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to CNSX:VRT / Seashore Organic Marijuana Corp on message board site Silicon Investor.

Vertex Pharmaceuticals (VRTX) Vertex Pharmaceuticals (VRTX) Vertex Pharmaceuticals (VRTX) VRTC: VERITEC INC. VRTC: VERITEC INC. VRTC: VERITEC INC.
Veritas (VRTS) Veritas (VRTS) Veritas (VRTS) Vertel (VRTL) 10xbagger in the making Vertel (VRTL) 10xbagger in the making Vertel (VRTL) 10xbagger in the making
Verity (VRTY) Verity (VRTY) Verity (VRTY) VRTX: Vertex Pharmaceuticals VRTX: Vertex Pharmaceuticals VRTX: Vertex Pharmaceuticals
VRTL: Vertel Corp. VRTL: Vertel Corp. VRTL: Vertel Corp. Virata Corporation (VRTA) Virata Corporation (VRTA) Virata Corporation (VRTA)
Techs, ANLY, PSCX,, TDS, VRTS, Articles Techs, ANLY, PSCX,, TDS, VRTS, Articles Techs, ANLY, PSCX,, TDS, VRTS, Articles BVR Technologies (NASDAQ:BVRT)Netgames BVR Technologies (NASDAQ:BVRT)Netgames BVR Technologies (NASDAQ:BVRT)Netgames